Dr. Baoxu Pang

I received my PhD with Cum Laude from the Netherlands Cancer Institute, defining a novel mode of action of a broadly used anti-cancer drug, doxorubicin, and its anthracycline members. I discovered that doxorubicin and other anthracycline members can also destabilize nucleosomes and evict histones from particular chromatin regions upon intercalating into the chromatin. As a result, the DNA damage response is attenuated and the epigenome of the cell is deregulated. After a brief period of post-doc training at the Netherlands Cancer Institute, I moved to the Department of Genetics, Stanford University in the US, where I developed unique genome-wide screen systems to study the function of the non-coding genome. In 2018 I started my research group at the Department of Cell and Chemical Biology. I was awarded the Antoni van Leeuwenhoek Prize from NKI-AvL, the Academic Excellence Award from China, the Gisela Thier Fellowship from LUMC, the Bas Mulder Award/Young lnvestigator Grant from Dutch Cancer Society (KWF), and the ERC Starting Grant from European Research Council.


  • Systematic identification of silencers in human cells.

    Pang B., Snyder MP.

    Nature Genetics. 2020, Feb24

  • Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin.

    Pang B.*, Qiao X.*, Janssen L., Velds A., Groothuis T., Kerkhoven R., Nieuwland M., Ovaa H., Rottenberg S., van Tellingen O., Janssen J., Huijgens P.,  Zwart W. and Neefjes J. 

    Nature Communications. 2013;4:1908 

  • Chemical profiling of the genome with anti-cancer drugs defines target specificities.

    Pang B.*†, de Jong J.*, Qiao X.*, Wessels L.F.A.†, Neefjes J.†.

    Nature Chemical Biology. 2015, 11, 472–480.


Collaborate with us

Looking for information on one of our topics, a new place to conduct your research or experienced research to join forces with?  Feel free to contact us.!

Read more